Key Points
- Dana Aftab, Exelixis EVP, sold 29,873 shares on Feb. 19 at an average price of $44.35 for a total of $1,324,867.55, trimming her stake by 4.31% to 664,024 shares — the transaction was disclosed on an SEC Form 4.
- Exelixis beat EPS estimates ($0.94 vs. $0.74) while reporting $598.7M in revenue (slightly below consensus but up 5.6% YoY); the stock trades around $44 with a market cap of $11.43B, P/E ~15.9 and PEG ~0.98.
- About 85.3% of EXEL is institutionally owned, and analysts have a consensus rating of "Hold" with an average target of $47.11 (mixed individual ratings across buy/hold/sell).
Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) EVP Dana Aftab sold 29,873 shares of the firm's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $44.35, for a total transaction of $1,324,867.55. Following the sale, the executive vice president directly owned 664,024 shares of the company's stock, valued at approximately $29,449,464.40. This trade represents a 4.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Exelixis Price Performance
Shares of Exelixis stock opened at $44.01 on Tuesday. The business has a 50-day simple moving average of $43.93 and a 200 day simple moving average of $41.29. Exelixis, Inc. has a one year low of $32.38 and a one year high of $49.62. The firm has a market capitalization of $11.43 billion, a price-to-earnings ratio of 15.89, a PEG ratio of 0.98 and a beta of 0.42.
Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.74 by $0.20. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The firm had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. During the same quarter in the previous year, the company posted $0.55 earnings per share. The company's quarterly revenue was up 5.6% on a year-over-year basis. On average, sell-side analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of EXEL. Richardson Financial Services Inc. increased its position in Exelixis by 95.1% in the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company's stock worth $25,000 after buying an additional 292 shares during the last quarter. Anchor Investment Management LLC lifted its holdings in Exelixis by 500.0% during the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 500 shares in the last quarter. Motiv8 Investments LLC bought a new position in Exelixis in the 4th quarter worth about $26,000. Root Financial Partners LLC bought a new position in shares of Exelixis in the third quarter valued at approximately $28,000. Finally, Acumen Wealth Advisors LLC purchased a new position in Exelixis during the fourth quarter valued at approximately $29,000. 85.27% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of brokerages have commented on EXEL. TD Cowen reissued a "buy" rating on shares of Exelixis in a report on Wednesday, November 5th. HC Wainwright upped their price target on Exelixis from $52.00 to $54.00 and gave the stock a "buy" rating in a report on Thursday, February 12th. Stifel Nicolaus increased their price target on Exelixis from $43.00 to $44.00 and gave the company a "hold" rating in a research report on Wednesday, February 11th. Wells Fargo & Company increased their target price on shares of Exelixis from $30.00 to $35.00 and gave the company an "equal weight" rating in a report on Wednesday, February 11th. Finally, Bank of America lowered shares of Exelixis from a "neutral" rating to an "underperform" rating and set a $41.00 price target on the stock. in a research report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Exelixis presently has a consensus rating of "Hold" and an average target price of $47.11.
Get Our Latest Research Report on Exelixis
About Exelixis
(
Get Free Report)
Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.
The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
